

## Press Release

### For Immediate Release

24 January 2025

### National Bioproducts Institute announces the appointment of Maishibe Ntlhane as new Chief Executive Officer

**Pinetown, South Africa** – National Bioproducts Institute NPC (NBI) is pleased to announce the appointment of Maishibe Ntlhane (CA(SA), CGMA, MBA (candidate)) as Chief Executive Officer, effective March 2025. Maishibe brings over 15 years of strategic leadership in healthcare finance, having previously served as Head of Finance (English West Africa) at Novartis.

For the past five years, Maishibe has been a key member of the NBI leadership team as Financial Director. Maishibe has already been instrumental in the development and growth of NBI, notably in the successful Plasma from Africa for Africans programme. Her leadership has been pivotal in advancing NBI's mission to enhance access to therapeutic and diagnostic protein supply to patients on the African continent and beyond.

Maishibe's deep commitment to improving access to quality medicine in Africa and other low-income regions, along with her finance and commercial expertise, positions her well to lead NBI through its next phase of growth. In her new role, she aims to further NBI's contributions to healthcare on the continent, solidifying its role as a key supplier of life-saving therapeutics.

David Stubbings, who has served as CEO since 2012, will retire in February 2025 after more than three decades of dedicated leadership and remarkable contributions to NBI. David's tenure has seen the organisation grow into a trusted and vital supplier of PDMPs and diagnostic kits in South Africa and neighbouring countries.

The NBI team expresses its heartfelt gratitude to David for his years of service and leadership and warmly welcomes Maishibe as the new CEO. NBI looks forward to an exciting future under her guidance as it continues to bring innovative and accessible healthcare solutions.

Issued by: Shanay Singh  
Head of Business Development  
National Bioproducts Institute NPC  
Shanay.singh@nbisa.org.za  
+27 (31) 714 6768

### **About National Bioproducts Institute**

National Bioproducts Institute NPC (NBI) is a private, non-profit, pharmaceutical manufacturer of human plasma-derived medicinal products. The company's manufacturing site and head office are located in Pinetown, KwaZulu-Natal, South Africa. NBI's range of pharmaceutical products includes clotting factors, immunoglobulins, albumin solutions and solvent detergent treated dried plasma. NBI's comprehensive range of plasma-derived medicinal products are registered with the South African Health Products Regulatory Authority. Several of NBI's products are listed in the South African Essential Medicines List as well as the World Health Organisation's Essential Drug List. NBI's Pharmaceutical products can be found in 6 countries across Africa. The Biotechnology department within the company develops and manufactures diagnostic kits and monoclonal antibodies for the South African and international diagnostic market. For more information:

[www.nbisa.org.za](http://www.nbisa.org.za)